TTY Biopharm Company Limited (TPEX:4105)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
73.90
-0.60 (-0.81%)
Apr 24, 2025, 1:30 PM CST
-2.64%
Market Cap 18.52B
Revenue (ttm) 5.89B
Net Income (ttm) 1.45B
Shares Out 248.65M
EPS (ttm) 5.82
PE Ratio 12.80
Forward PE 15.20
Dividend 4.20 (5.75%)
Ex-Dividend Date Mar 27, 2025
Volume 407,044
Average Volume 1,190,655
Open 75.00
Previous Close 74.50
Day's Range 73.90 - 75.00
52-Week Range 66.20 - 80.90
Beta -0.02
RSI 51.70
Earnings Date May 14, 2025

About TTY Biopharm Company

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yond... [Read more]

Sector Healthcare
Founded 1960
Employees 342
Stock Exchange Taipei Exchange
Ticker Symbol 4105
Full Company Profile

Financial Performance

In 2024, TTY Biopharm Company's revenue was 5.89 billion, an increase of 7.05% compared to the previous year's 5.51 billion. Earnings were 1.45 billion, an increase of 28.45%.

Financial Statements

News

There is no news available yet.